"
Team:UNC-Chapel Hill/Project
From 2014.igem.org
|
||||||||||||||||
| DIABETES MELLITUS | ||||
Project IntroductionDiabetes mellitus is prevalent throughout the world especially in the United States and Mexico. As a treatable disease, diabetes has fallen in the shadow of more life threatening diseases. Although treatable, diabetes can be life threatening, especially to those who cannot afford treatment options. As a solution, we propose a protein controlled system to sense glucose concentrations and release the needed proteins in response. This project executes the first crucial steps of creating a cost effective and accurate means of glucose sensing via the use of Escherichia coli. |
Results
|
|
| Abstract | Background | Type One | Type Two | Modeling | References |
AbstractLorem ipsum ad his scripta blandit partiendo, eum fastidii accumsan euripidis in, eum liber hendrerit an. Qui ut wisi vocibus suscipiantur, quo dicit ridens inciderint id. Quo mundi lobortis reformidans eu, legimus senserit definiebas an eos. Eu sit tincidunt incorrupte definitionem, vis mutat affert percipit cu, eirmod consectetuer signiferumque eu per. In usu latine equidem dolores. Quo no falli viris intellegam, ut fugit veritus placerat per. |
|
BackgroundDiabetesIn the National Diabetes Statistics Report of 2014 released by the National Center for Chronic Disease Prevention and Health Promotion it was reported that 29.1 million Americans (9.3% of the US population) have diabetes mellitus. The cost both direct and indirect of diabetes treatment is estimated to be 245 billion dollars, and the disease remains the 7th leading cause of premature death in the United States. With the prevalence of diabetes mellitus in the US population the 2014 UNC Chapel Hill iGEM team felt an obligation to address the problem. CRP-cAMP ComplexLorem ipsum ad his scripta blandit partiendo, eum fastidii accumsan euripidis in, eum liber hendrerit an. Qui ut wisi vocibus suscipiantur, quo dicit ridens inciderint id. Quo mundi lobortis reformidans eu, legimus senserit definiebas an eos. Eu sit tincidunt incorrupte definitionem, vis mutat affert percipit cu, eirmod consectetuer signiferumque eu per. In usu latine equidem dolores. Quo no falli viris intellegam, ut fugit veritus placerat per. |
Type One DiabetesSolutionType 1 diabetes is characterized by the body’s immune system destroying insulin producing cells which leads the body to no longer producing insulin, a hormone that promotes the uptake of glucose by cells. We provide a solution for this problem through the creation of a pseudo beta cell that is able to produce insulin in the presence of high glucose level. |
Type Two DiabetesSolutionType 2 diabetes is characterized by the body being inefficient in its use of insulin (insulin resistance) which causes the pancreas to decrease insulin production (insulin deficiency). Our potential solution for this is to have pseudo L cells release GLP-1 to promote insulin production. GLP-1 is an incretin. Incretins are a group of gastrointestinal hormones that stimulate a decrease in blood glucose levels. GLP-1 has been shown to promote insulin production and also to decrease glucagon production. Glucagon is a peptide hormone produced by alpha cells of the pancreas that raises the concentration of glucose in the bloodstream. |
ReferencesThank YouLorem ipsum ad his scripta blandit partiendo, eum fastidii accumsan euripidis in, eum liber hendrerit an. Qui ut wisi vocibus suscipiantur, quo dicit ridens inciderint id. Quo mundi lobortis reformidans eu, legimus senserit definiebas an eos. Eu sit tincidunt incorrupte definitionem, vis mutat affert percipit cu, eirmod consectetuer signiferumque eu per. In usu latine equidem dolores. Quo no falli viris intellegam, ut fugit veritus placerat per. |
